中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非酒精性脂肪性肝病患者血清维生素A水平、肝脏脂肪含量与胰岛素抵抗的相关性分析

丁智勇 卜乐 鲁鸿燕 饶正轩

引用本文:
Citation:

非酒精性脂肪性肝病患者血清维生素A水平、肝脏脂肪含量与胰岛素抵抗的相关性分析

DOI: 10.3969/j.issn.1001-5256.2017.12.021
基金项目: 

崇明县科学技术委员会科技项目(cky2017-21); 

详细信息
  • 中图分类号: R575.5

Correlation of liver fat content with serum vitamin A level and insulin resistance in patients with nonalcoholic fatty liver disease

Research funding: 

 

  • 摘要:

    目的观察和分析非酒精性脂肪性肝病(NAFLD)患者肝脏脂肪含量(LFC)与血清维生素A(VA)水平及胰岛素抵抗(IR)之间的关系。方法征集2016年2月-2017年1月上海市崇明地区初诊NAFLD患者200例和健康志愿者98例。根据口服75 g葡萄糖耐量试验和胰岛素释放试验,将NAFLD患者分为单纯NAFLD组(n=91)、NAFLD合并糖调节受损(IGR)组(n=69),NAFLD合并2型糖尿病(T2DM)组(n=40),另将98例健康志愿者作为健康对照组。用稳态模型评估IR,用高效液相色谱法检测血清VA水平,采用3.0 T质子磁共振波谱进行LFC检测。符合正态分布的计量资料多组间比较采用单因素方差分析,进一步两两比较采用LSD-t检验;不符合正态分布的计量资料组间比较采用Kruskal-Wallis H检验,进一步两两比较采用Mann-Whitmey U检验。计数资料组间比较采用Pearsonχ2检验。相关性分析采用Spearman相关性分析法。结果健康对照组、单纯NAFLD组、NAFLD合并IGR组和NAFLD合并T2DM组4组间FPG、葡萄糖耐量试验负荷后2 h血糖(2h PG...

     

  • [1]FAN JG, ZHU J, LI XJ, et al.Prevalence of and risk factors for fatty liver in a general population of Shanghai, China[J].J Hepatol, 2005, 43 (3) :508-514.
    [2]MAILAMUGULI, JIANAERGULI XK, CAI W, et al.Association between non-high-density lipoprotein cholesterol and nonalcoholic fatty liver disease in postmenopausal Uyghur women in Xinjiang, China[J].J Clin Hepatol, 2016, 32 (6) :1155-1159. (in Chinese) 买拉木古丽, 加那尔古丽·夏坎, 蔡雯, 等.非高密度脂蛋白胆固醇水平与新疆维吾尔族绝经后女性非酒精性脂肪性肝病的关系[J].临床肝胆病杂志, 2016, 32 (6) :1155-1159.
    [3]TILG H, MOSCHEN AR, RODEN M.NAFLD and diabetes mellitus[J].Nat Rev Gastroenterol Hepatol, 2017, 14 (1) :32-42.
    [4]TARGHER G, MARCHESINI G, BYRNE CD.Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease:causal association or epiphenomenon?[J].Diabetes Metab, 2016, 42 (3) :142-156.
    [5]ZHAO S, LI R, LI Y, et al.Roles of vitamin A status and retinoids in glucose and fatty acid metabolism[J].Biochem Cell Biol, 2012, 90 (2) :142-152.
    [6]European Association for the Study of the Liver (EASL) ;European Association for the Study of Diabetes (EASD) ;European Association for the Study of Obesity (EASO) .EASL-EASD-EASOClinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J].J Hepatol, 2016, 64 (6) :1388-1402.
    [7] Chinese Society of Diabetes, Chinese Medical Association.Guidelines for the prevention and treatment of type 2 diabetes in China (version 2013) [J].Chin J Diabetes, 2014, 22 (8) :2-42. (in Chinese) 中华医学会糖尿病学分会.中国2型糖尿病防治指南 (2013年版) [J].中国糖尿病杂志, 2014, 22 (8) :2-42.
    [8]SZCZEPANIAK LS, NURENBERG P, LEONARD D, et al.Magnetic resonance spectroscopy to measure hepatic triglyceride content:prevalence of hepatic steatosis in the general population[J].Am J Physiol Endocrinol Metab, 2005, 288 (2) :462-468.
    [9]BU L, GAO M, QU S, et al.Intraperitoneal injection of clodronate liposomes eliminates visceral adipose macrophages and blocks high-fat diet-induced weight gain and development of insulin resistance[J].AAPS J, 2013, 15 (4) :1001-1011.
    [10]ADAMS LA, LYMP JF, ST SAUVER J, et al.The natural history of nonalcoholic fatty liver disease:a population-based cohort study[J].Gastroenterology, 2005, 129 (1) :113-121.
    [11]SUGANAMI T, TANAKA M, OGAWA Y.Adipose tissue inflammation and ectopic lipid accumulation[J].Endocr J, 2012, 59 (10) :849-857.
    [12]LAURENS C, MORO C.Intramyocellular fat storage in metabolic diseases[J].Horm Mol Biol Clin Investig, 2016, 26 (1) :43-52.
    [13]LEWIS GF, CARPENTIER A, ADELI K, et al.Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes[J].Endocr Rev, 2002, 23 (2) :201-229.
    [14]WANG Z, HU DY.Research advances in quantitative evaluation of liver fat in patients with nonalcoholic fatty liver disease[J].J Clin Hepatol, 2013, 29 (12) :894-896. (in Chinese) 王梓, 胡道予.量化评价非酒精性脂肪性肝病患者肝脏脂肪含量的研究进展[J].临床肝胆病杂志, 2013, 29 (12) :894-896.
    [15]KOTRONEN A, JUURINEN L, TIIKKAINEN M, et al.Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes[J].Gastroenterology, 2008, 135 (1) :122-130.
    [16]LI R, CHEN W, LI Y, et al.Retinoids synergized with insulin to induce Srebp-1c expression and activated its promoter via the two liver X receptor binding sites that mediate insulin action[J].Biochem Biophys Res Commun, 2011, 406 (2) :268-272.
    [17]MILLER VA, RIGAS JR, MUINDI JR, et al.Modulation of alltrans retinoic acid pharmacokinetics by liarozole[J].Cancer Chemother Pharmacol, 1994, 34 (6) :522-526.
    [18]OLIVEROS LB, DOMENICONI MA, VEGA VA, et al.Vitamin Adeficiency modifies lipid metabolism in rat liver[J].Br J Nutr, 2007, 97 (2) :263-272.
    [19]CHERTOW BS, GOKING NQ, DRISCOLL HK, et al.Effects of all-trans-retinoic acid (ATRA) and retinoic acid receptor (RAR) expression on secretion, growth, and apoptosis of insulinsecreting RINm5F cells[J].Pancreas, 1997, 15 (2) :122-131.
    [20]KANE MA, FOLIAS AE, PINGITORE A, et al.Identification of 9-cis-retinoic acid as a pancreas-specific autacoid that attenuates glucose-stimulated insulin secretion[J].Proc Nat Acad Sci, 2010, 107 (50) :21884-21889.
  • 加载中
计量
  • 文章访问数:  437
  • HTML全文浏览量:  53
  • PDF下载量:  94
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-07-07
  • 出版日期:  2017-12-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回